Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations Life Science Investing
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates Life Science Investing
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics Life Science Investing
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions Life Science Investing
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic , and Pharmacodynamic Data Life Science Investing
Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting Life Science Investing
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting Life Science Investing
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients Life Science Investing
Republic Technologies Announces Definitive Investment Agreement for Up to US$100 Million Secured Convertible Note Facility Medical Device Investing
